Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: a case series and review of the literature
- PMID: 27862048
- DOI: 10.1002/pd.4966
Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: a case series and review of the literature
Abstract
Objective: Alpha thalassemia major (ATM) is often fatal in utero due to severe hydrops fetalis. Although in utero transfusions (IUTs) are increasingly used to allow fetal survival in ATM, prenatal and postnatal outcomes are not well described.
Methods: We retrospectively reviewed cases of ATM at our institution treated with consecutive IUT. Clinical records were reviewed for transfusion history, neurodevelopmental outcomes, anatomic abnormalities, survival to hematopoietic cell transplantation, and transfusion independence. A systematic review was performed, and additional reported cases are discussed.
Results: Three patients who underwent IUT for ATM were identified, and review of the literature revealed 17 reported cases. Of patients who received IUT, reported neurodevelopmental deficits occurred in 29% (4/14) and anatomic abnormalities in 55% (11/20). Four patients eventually underwent successful hematopoietic cell transplantation. Transfusion volumes were less than suggested guidelines for other causes of fetal anemia in 91.7% of the transfusions.
Conclusion: This series demonstrates the potential for achieving full fetal development with normal neurologic outcomes in those affected by ATM. It provides support for continued patient and provider education about current benefits and risks of active prenatal therapy for fetuses with ATM, as well as continued research to optimize therapeutic strategies such as in utero transplantation. © 2016 John Wiley & Sons, Ltd.
© 2016 John Wiley & Sons, Ltd.
Similar articles
-
The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry.Blood Adv. 2023 Jan 24;7(2):269-279. doi: 10.1182/bloodadvances.2022007823. Blood Adv. 2023. PMID: 36306387 Free PMC article.
-
Perinatal outcomes of intrauterine transfusion for foetal anaemia due to red blood cell alloimmunisation.J Obstet Gynaecol. 2020 Jul;40(5):649-653. doi: 10.1080/01443615.2019.1647521. Epub 2019 Aug 29. J Obstet Gynaecol. 2020. PMID: 31462132
-
Alpha thalassemia major--new mutations, intrauterine management, and outcomes.Hematology Am Soc Hematol Educ Program. 2009:35-41. doi: 10.1182/asheducation-2009.1.35. Hematology Am Soc Hematol Educ Program. 2009. PMID: 20008180 Review.
-
[Intrauterine transfusión in alloimmunization Rh in México 1987-2008].Ginecol Obstet Mex. 2010 Sep;78(9):469-77. Ginecol Obstet Mex. 2010. PMID: 21961364 Spanish.
-
Advances in the management of α-thalassemia major: reasons to be optimistic.Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):592-599. doi: 10.1182/hematology.2021000295. Hematology Am Soc Hematol Educ Program. 2021. PMID: 34889445 Free PMC article. Review.
Cited by
-
Dual α-globin and truncated EPO receptor knockin restores hemoglobin production in α-thalassemia-derived red blood cells.bioRxiv [Preprint]. 2024 May 7:2023.09.01.555926. doi: 10.1101/2023.09.01.555926. bioRxiv. 2024. PMID: 38766216 Free PMC article. Preprint.
-
Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease.Eur J Pediatr. 2023 Jun;182(6):2509-2519. doi: 10.1007/s00431-023-04900-w. Epub 2023 Mar 31. Eur J Pediatr. 2023. PMID: 36997768 Free PMC article. Review.
-
When is the best time to screen and evaluate for treatable genetic disorders?: A lifespan perspective.Am J Med Genet C Semin Med Genet. 2023 Mar;193(1):44-55. doi: 10.1002/ajmg.c.32036. Epub 2023 Mar 6. Am J Med Genet C Semin Med Genet. 2023. PMID: 36876995 Free PMC article. Review.
-
The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry.Blood Adv. 2023 Jan 24;7(2):269-279. doi: 10.1182/bloodadvances.2022007823. Blood Adv. 2023. PMID: 36306387 Free PMC article.
-
Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies.Pharmaceutics. 2022 Apr 5;14(4):793. doi: 10.3390/pharmaceutics14040793. Pharmaceutics. 2022. PMID: 35456627 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous

